Home / Bioanalytical and biomarker services / Preclinical services / In vivo
In Vivo CRO Services
Comprehensive functional evaluations and established in vivo models designed to accurately measure therapeutic efficacy for rare disease programs.
Rigorous testing for critical endpoints
As an experienced in vivo pharmacology CRO, we conduct rigorous in vivo efficacy studies to quantify therapeutic impact across specialized rare disease models. Our senior scientists help you establish the most appropriate context of use early to ensure your study design is strictly fit-for-purpose and generates defensible data for your IND submission.
Functional outcomes and comprehensive analysis
We apply established standard operating procedures to evaluate subtle therapeutic signals and measure critical biomarkers.
Skeletal muscle function
We evaluate grip strength, treadmill exhaustion, rotarod performance and voluntary running wheel metrics alongside gold-standard in vivo and ex vivo muscle force testing to reliably quantify physical improvement.
Cardiopulmonary function and in vivo imaging
We utilize advanced echocardiography and plethysmography to accurately assess critical heart and respiratory outcomes, alongside IVIS imaging to detect in vivo inflammation and quantify labeled compounds.
Tissue pathology and biomarker detection
We map disease mechanisms by measuring inflammation, degeneration, regeneration and fiber size across specific tissue samples, utilizing established bioassays such as Western blot, RT-PCR, Serum CK and Luminex for precise biomarker detection.
Discuss your in vivo study design
Engage our senior scientists to establish a rigorous in vivo testing plan for your rare disease program.
Specialized expertise in rare disease models
AGADA Biosciences applies focused scientific rigor to evaluate complex disease models. We leverage vast historical data and deep insight across multiple rare disease targets to benchmark your study design and ensure accurate statistical powering.
Historical benchmarking:
We leverage archival data from over 100 trials in mouse models of muscular dystrophy to accurately power your efficacy studies.
Extensive model experience:
We maintain specialized expertise in established Duchenne models and possess deep capability across limb-girdle and congenital muscular dystrophies.
Early risk identification:
We proactively address scientific and operational challenges during pilot studies to ensure readiness for larger efficacy evaluations.
Harmonized workflows:
We align our preclinical standard operating procedures directly with our clinical protocols to drastically reduce downstream technology transfer time.
Predictable schedules for efficacy testing
We design pilot studies and comprehensive evaluations that maximize your limited resources and keep your program moving forward.
Built to integrate
AGADA Biosciences acts as a collaborative partner that integrates smoothly into your existing vendor ecosystem. We can independently execute your in vivo studies or integrate directly with your other research partners to advance your program.
Direct access to senior scientific oversight
Our lean scale keeps scientific expertise close to the work, so decisions are made in minutes rather than weeks.
Context of use alignment:
We help define the exact regulatory context early so your in vivo endpoints remain strictly fit for purpose.
Live animal imaging:
We track skeletal muscle inflammation in live animals using advanced near-infrared cathepsin B technology.
Regulatory readiness:
We operate in compliance with GLP guidelines to ensure your preclinical research yields data regulators can trust.
Smooth transitions:
We eliminate silos between early research and clinical execution to give your therapy the best chance of first-time success.
Start a conversation
Reach out to our team to ensure your in vivo data is reliable and ready for IND submission.
Where history meets innovation
In the heart of downtown Halifax, AGADA has transformed a historic building into a modern facility dedicated to advancing rare disease therapeutics. Take a closer look at our laboratories, scientific capabilities and dedicated team and discover how our unique location and collaborative environment support the work we do for clients and patients worldwide.
Quality and compliance
We operate in strict compliance with GCP, GLP and GDPR regulations to ensure your data remains interpretable and defensible. Every team member must hold a CITI certification before supporting any sponsor trial.
Meet our scientific leadership
Our founders and senior scientists are globally recognized leaders in rare and neuromuscular disease research, bringing decades of specialized expertise to your program.
News and resources
AGADA Biosciences executes rigorous in vivo efficacy studies across specialized rare disease models to accurately measure therapeutic impact and support your IND submission.
